The intriguing evidence that ATF5 exerts prosurvival effects in glioma and not in healthy brain tissue led us to consider whether ATF5 downregulation, mediated by m6A enrichment of ATF5 transcripts, might serve as a downstream effector of reduced tumor growth. This evidence concerns the gene ATF5 and central nervous system cancer.